Ovid Therapeutics (OVID) EPS (Basic) Growth (3y) (2019 - 2026)
Ovid Therapeutics (OVID) EPS (Basic) Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 37.73% |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | 86.43% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 45.89% |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | -21.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.44% |
| Dec 31, 2025 | 39.12% |
| Sep 30, 2025 | -52.96% |
| Jun 30, 2025 | -3.53% |
| Mar 31, 2025 | -30.05% |
| Dec 31, 2024 | -72.24% |
| Sep 30, 2024 | -5.60% |
| Jun 30, 2024 | 36.01% |
| Mar 31, 2024 | -27.28% |
| Dec 31, 2023 | 16.80% |
| Sep 30, 2023 | 74.81% |
| Jun 30, 2023 | 79.36% |
| Mar 31, 2023 | 82.88% |
| Dec 31, 2022 | 67.55% |
| Sep 30, 2022 | 72.86% |
| Jun 30, 2022 | 69.06% |
| Mar 31, 2022 | 71.07% |
| Dec 31, 2021 | 9.73% |
| Sep 30, 2021 | 31.71% |
| Jun 30, 2021 | 23.76% |